Thibaut du Fayet

Thibaut du Fayet is the CEO of Phaxiam Therapeutics, where he utilizes his expertise in the biotechnology industry. Prior to this role, Thibaut served as the CEO and COO of Pherecydes Pharma, a company focusing on precision phage therapy to combat resistant bacterial infections. With a background in strategic marketing, corporate development, and alliance management at companies like Transgene, bioMerieux, and Rhone Poulenc Chimie, Thibaut brings a wealth of experience to his current role. His career highlights include leading strategic projects, managing research and development portfolios, and implementing innovative marketing processes. Thibaut's educational background includes degrees in Finance and Business from ESSEC Business School.